- Home
- PROF vs GLSI Comparison
PROF vs GLSI Comparison
Compare PROF & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROF
- GLSI
- Stock Information
- Founded
- PROF N/A
- GLSI 2006
- Country
- PROF Canada
- GLSI United States
- Employees
- PROF N/A
- GLSI N/A
- Industry
- PROF Medical/Dental Instruments
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- PROF Health Care
- GLSI Health Care
- Exchange
- PROF Nasdaq
- GLSI Nasdaq
- Market Cap
- PROF 149.7M
- GLSI 134.6M
- IPO Year
- PROF N/A
- GLSI 2020
- Fundamental
- Price
- PROF $5.86
- GLSI $11.42
- Analyst Decision
- PROF Strong Buy
- GLSI Strong Buy
- Analyst Count
- PROF 1
- GLSI 1
- Target Price
- PROF $11.00
- GLSI $39.00
- AVG Volume (30 Days)
- PROF 34.8K
- GLSI 81.8K
- Earning Date
- PROF 08-07-2025
- GLSI 08-13-2025
- Dividend Yield
- PROF N/A
- GLSI N/A
- EPS Growth
- PROF N/A
- GLSI N/A
- EPS
- PROF N/A
- GLSI N/A
- Revenue
- PROF $11,862,000.00
- GLSI N/A
- Revenue This Year
- PROF $71.17
- GLSI N/A
- Revenue Next Year
- PROF $134.25
- GLSI N/A
- P/E Ratio
- PROF N/A
- GLSI N/A
- Revenue Growth
- PROF 75.01
- GLSI N/A
- 52 Week Low
- PROF $3.90
- GLSI $8.06
- 52 Week High
- PROF $11.42
- GLSI $17.00
- Technical
- Relative Strength Index (RSI)
- PROF 47.74
- GLSI 58.35
- Support Level
- PROF $5.54
- GLSI $11.06
- Resistance Level
- PROF $5.87
- GLSI $12.54
- Average True Range (ATR)
- PROF 0.25
- GLSI 0.73
- MACD
- PROF -0.04
- GLSI 0.10
- Stochastic Oscillator
- PROF 33.09
- GLSI 52.69
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.